What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Cardiology
Harvey D. White mainly focuses on Internal medicine, Myocardial infarction, Cardiology, Surgery and Percutaneous coronary intervention.
His is involved in several facets of Internal medicine study, as is seen by his studies on Acute coronary syndrome, Randomized controlled trial, Stroke, Coronary artery disease and Infarction.
His study explores the link between Acute coronary syndrome and topics such as Platelet aggregation inhibitor that cross with problems in Gastroenterology.
His Cardiology research incorporates elements of Heparin and Hazard ratio.
His Surgery research is multidisciplinary, relying on both Antithrombotic and Risk factor.
His research on Percutaneous coronary intervention also deals with topics like
- Conventional PCI and related Anesthesia,
- Angina and related Glycoprotein IIb/IIIa inhibitors.
His most cited work include:
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (8500 citations)
- Third universal definition of myocardial infarction (5502 citations)
- Universal definition of myocardial infarction (3367 citations)
What are the main themes of his work throughout his whole career to date?
Harvey D. White mainly focuses on Internal medicine, Cardiology, Myocardial infarction, Acute coronary syndrome and Surgery.
He incorporates Internal medicine and In patient in his studies.
His work on Hazard ratio expands to the thematically related Cardiology.
His research in Myocardial infarction tackles topics such as Randomized controlled trial which are related to areas like Clinical trial.
His Acute coronary syndrome study integrates concerns from other disciplines, such as Platelet aggregation inhibitor, Aspirin, Alirocumab and ST segment.
Surgery is closely attributed to ST elevation in his work.
He most often published in these fields:
- Internal medicine (83.09%)
- Cardiology (68.68%)
- Myocardial infarction (51.13%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (83.09%)
- Cardiology (68.68%)
- Myocardial infarction (51.13%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Cardiology, Myocardial infarction, Acute coronary syndrome and Percutaneous coronary intervention.
Harvey D. White conducts interdisciplinary study in the fields of Internal medicine and In patient through his research.
His studies in Myocardial infarction integrate themes in fields like Platelet aggregation inhibitor, Randomized controlled trial, Surgery and Coronary artery disease.
Within one scientific family, Harvey D. White focuses on topics pertaining to Darapladib under Coronary artery disease, and may sometimes address concerns connected to Proportional hazards model.
Harvey D. White has included themes like Aspirin, ST segment and Cohort in his Acute coronary syndrome study.
His research investigates the connection between Percutaneous coronary intervention and topics such as Conventional PCI that intersect with problems in Reperfusion therapy.
Between 2015 and 2021, his most popular works were:
- Fourth universal definition of myocardial infarction (2018) (1492 citations)
- Initial invasive or conservative strategy for stable coronary disease. (390 citations)
- Cardiovascular efficacy and safety of bococizumab in high-risk patients (361 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Surgery
The scientist’s investigation covers issues in Internal medicine, Myocardial infarction, Cardiology, Acute coronary syndrome and Stroke.
His work in the fields of Internal medicine, such as Coronary artery disease, Unstable angina and Randomized controlled trial, overlaps with other areas such as In patient.
The various areas that he examines in his Myocardial infarction study include Darapladib and Hazard ratio.
His Cardiology study incorporates themes from Clinical endpoint, Framingham Risk Score and Confidence interval.
He has researched Acute coronary syndrome in several fields, including Thrombolysis, Mace, Disease, Infarction and ST segment.
His biological study spans a wide range of topics, including Vorapaxar, Statin, Regimen, Rate ratio and Atrial fibrillation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
